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Abstract
Background: One third of travellers to low- and middle-income regions of the tropics and subtropics become colonized
by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). The risk varies by destination and, for each
traveller, may be substantially further increased by travellers’ diarrhoea (TD) and antibiotic use. Despite the risk of TD in
Africa, ESBL-PE acquisition rates in all studies are lower there than in Asia. Africa has become increasingly popular as a
destination for international travellers, yet minimal data are available from the continent’s subregions and countries.
Methods: We analysed subregion- and country-specific data on carriage and risk factors for ESBL-PE colonization pooled
from three prospective studies conducted between 2009 and 2013 among Finnish and Dutch travellers. The data were
subjected to multivariable analysis of risk factors. In addition, we compared our data to two recent large investigations
reporting data by subregion and country.
Results: Our joint analysis comprised data on 396 travellers. The ESBL-PE colonization rate was highest in Northern Africa,
followed by Middle and Eastern Africa, and lowest in Southern and Western Africa. Of individual countries with more than
15 visitors, the highest rates were seen for Egypt (12/17; 70.6%), Ghana (6/23; 26.1%), and Tanzania (14/81; 17.3%);
the rates among travellers to Egypt were comparable to those reported in South and Southeast Asia. In a pooled
multivariable analysis, travel destination, age, overnight hospitalisation abroad, TD, and use of fluoroquinolones
were independently associated with increased ESBL-PE colonization rates.
Conlusions: Even in areas with relatively low risk of colonization, antimicrobials clearly predispose to colonization
with ESBL-PE. Travellers to Africa should be cautioned against unnecessary use of antibiotics.
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Background
Every third traveller from industrialised countries that
visits developing regions becomes colonized by extended
-spectrum beta-lactamase-producing Enterobacteriaceae
(ESBL-PE) [1–11]. While rates as high as 88% have been
reported for travellers to South Asia [4–8, 10, 11] and 69%
to Southeast Asia [4, 6–8, 10, 11], considerably lower risks
have been detected among travellers to the African con-
tinent, varying between 12 and 45% [3, 4, 6–8, 10, 11].
Data on colonization among visitors to various African
countries or subregions remain scarce, as the vast majority
of prospective studies report acquisition rates either for
the whole continent [1, 9] or only part of the subregions
[3, 4, 6, 8–10, 12, 13]; a few investigations provide data
on a number of individual countries [7, 11]. Travel destin-
ation, antibiotic use, age, and travellers’ diarrhoea (TD)
have been identified as major risk factors. Several other
additional factors have been shown in single studies: type of
travel, meal location and consumption of certain food prod-
ucts, such as ice cream and pastries [1, 3–7, 9–11, 14].
While these factors all predispose to ESBL-PE colonization
in general, studies presenting colonization risk factors by
individual geographic areas are few [5, 11], and none have
focused exclusively on Africa. As the continent attracts
increasing numbers of travellers [15], we decided to re-
view the data published and pool subregion-derived
findings of our three earlier investigations [4 6, 10]. Com-
bining these data with subregional carriage rates from two
recent studies [7, 11], our paper offers an insight into the
subregion-related colonization risk of travellers to Africa.
Methods
Study design, volunteers and samples
To assess the colonization rates of ESBL-PE in Africa,
we combined the data of travellers to Africa from three
large studies:
(1) Finnish study by Kantele et al. [6]. The volunteers
travelled in 2009–2010; 196 of the 430 (45.6%) travelled
in Africa. Faecal samples were used for analyses.
(2) Dutch study I by Paltansing et al. [4]. The volunteers
travelled in 2011; 103 of 338 (30.5%) travelled in
Africa. Rectal swabs were used for analyses.
(3) Dutch study II by Reuland et al. [10]. The
volunteers travelled in 2012–2013 (of the travellers
reviewed here, all but one travelled in 2012); 97 of
418 (23.2%) travelled in Africa; 63 (64.9%) faecal
samples and 34 (35.1%) rectal swabs were analysed.
In the original article, the authors report that the
colonization rates were similar regardless of sample
technique.
For all three prospective studies, the volunteers provided
both pre- and post-travel stool samples/rectal swabs. Of the
14 (3.5%) travellers with pre-travel samples positive for
ESBL-PE, three had the same strain detected in post-travel
samples. In six volunteers, the post-travel sample was nega-
tive; these were included in the ESBL-PE(−) group. The
five that contracted a different type of ESBL-PE during
travel were included in the ESBL-PE(+) group. Travel-
lers who contracted a new ESBL-PE strain during travel
constituted the ESBL-PE(+) group, while all others
belonged to the ESBL-PE(−) group. The following infor-
mation was available from all three studies in comparable
format: travel itinerary, travel duration, travel dates, age,
sex, antimicrobial usage, occurrence of TD, and possible
hospitalisation abroad (overnight stay or more).
In all studies, written informed consent was obtained
from all participants and the Ethics Committees in the
respective organisations approved the study protocols.
Collection of stool samples and identification of ESBL-PE
strains
We have described earlier in detail the approaches to col-
lection of samples (stools or swabs) and methods used for
identification of ESBL-PE and carbapenemase-producing
Enterobacteriaceae (CPE) [4, 6, 10].
Definition of TD and geographical subregions
For the purpose of the present study, TD was defined as
three or more loose or liquid stools per day. Geographical
subregions in Africa were defined according to the United
Nations [16]: Southern Africa, Western Africa, Middle
Africa, Eastern Africa, and Northern Africa. Travellers
visiting more than one subregion in Africa were cate-
gorised on the basis of longest stay.
Statistical analyses
Statistical analyses were carried out with SPSS software
version 24 (IBM Corp, Armonk, NY) and Stata version
15.1 (StataCorp. College Station, TX). Binomial regression
model was used to obtain profile likelihood confidence
intervals for the proportions of travellers with given risk
factors and positive for ESBL-PE. The chi-square test,
Fisher’s exact test or binary logistic regression analysis
were used to compare categorical variables when applic-
able. Binary logistic regression was used with continuous
variables. Variables with a p-value < 0.2 in the univariate
analysis for ESBL-PE colonization were subjected to mul-
tivariable analysis together with doxycycline as antimalar-
ial, gender and duration of travel in days. The shape of the
form for travel duration and age were assessed by cubic
splines and appeared log-linear. The interaction between
variables of interest and studies was assessed. The final
model was built using binary logistic regression analysis
with a stepwise backward selection of variables by Akaike
Information Criteria (AIC). Factors with 95% confidence
intervals ranging only either above or below 1 were
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considered significant. The three studies pooled in the
present paper [4, 6, 10] and the two others [7, 11] used for
comparisons were all brought together to produce a forest
plot analysis. Heterogeneity between studies in forest plot
was measured with I2; values above 75% were considered
high, 25–75% moderate, and below 25%. For our pooled
data, the interaction between studies and geographical
subregions was analysed in the multivariable model.
Results
Demographic data, background characteristics, and
occurrence of TD
Demographic data on travellers are presented in Table 1.
Of the 396 travellers included in this study, 237 (59.8%)
were women. The median age was 36 years (IQR 27–53)
and the median duration of travel 19 days (IQR 14–25).
One fourth of the travellers (n = 105; 26.5%) had visited
more than one country in Africa. The majority of the
travellers visited either Western (27.8%) or Eastern
(46.7%) Africa. Twenty-three (5.8%) had visited more
than one subregion in Africa. In addition to Africa (or
Europe en route to Africa), two volunteers (0.5%) had
visited Jordania and two (0.5%) United Arab Emirates.
TD rates were lowest in Southern Africa (15/58; 25.9%);
in other areas 37.8–46.7% of travellers contracted TD
(Table 2.). Of the 44 (11.1% of all travellers) courses of
antibiotics, 30 (68.2%) were taken for TD. Eight (2.0% of
all travellers) used beta-lactam antibiotics and 25 (6.3%)
used fluoroquinolone antibiotics during travel.
ESBL-PE acquisition rates by subregion in the pooled data
In the pooled data (Table 2, Fig. 1), 61 (15.4%) travellers
became colonized by ESBL-PE; one Dutch traveller to
Egypt became colonized by CPE. The highest ESBL-PE
colonization rates were seen among travellers to Northern
Africa (12/28; 42.9%), followed by Middle Africa (4/15;
26.7%) and Eastern Africa (30/185; 16.2%). Of travellers to
Western and Southern Africa, 10.0% (11/110) and 6.9%
(4/58), respectively, acquired ESBL-PE (Tables 1 and 2).
Of the nine countries with more than 15 visitors
(Table 3), the highest ESBL-PE acquisition rates were
seen among travellers to Egypt (12/17; 70.6%), Ghana (6/23;
26.1%), Tanzania (14/81; 17.3%), Uganda (4/26; 15.4%) and
Kenya (12/82; 14.6%). As for the lowest colonization rates,
of the 26 travellers to Senegal, three (11.5%) became colo-
nized by ESBL-PE, in South Africa, 5/49 (10.2%) became
colonized and in the Gambia the rate was only 3.4% (2/58);
none of the 21 visitors to Namibia acquired ESBL-PE.
Results of the multivariable analysis for risk factors of
ESBL-PE colonization in Africa
The initial univariate analysis (Table 1) detected the fol-
lowing factors with p < 0.2: age, original study, sampling
technique, subregion in Africa, use of fluoroquinolones,
beta-lactams or other AB/regimen not known, TD, and
overnight hospitalisation abroad. When all of these fac-
tors, together with gender, duration of travel, and use of
doxycycline as antimalarial were subjected to multivari-
able analysis, the following were found to be independ-
ently associated with increased risk: travel to Northern
Africa, overnight hospitalisation abroad, age, TD and use
of fluoroquinolones (Table 1).
Results of meta-analysis of five studies
Table 4 and forest plot analysis (Fig. 2) show the ESBL-PE
colonization rates from the three studies pooled [4, 6, 10],
together with investigations by Ruppé et al. and Arcilla et
al. [7, 11] in relation to geographical subregion visited. For
Southern and Northern Africa, heterogeneity between the
five studies appeared low (I2 = 0.0 and 0.0%, respectively),
for Middle Africa moderate (I2 52.0%), and Eastern and
Western Africa high (I2 88.9 and 90.4%, respectively). In
the multivariable regression model of our pooled data, the
interaction between subregions and the three studies was
not found significant at 5% significance level.
Discussion
Africa is a continent with increasing numbers of travel-
lers [15]. When pooling subregion-/country-specific data
from three traveller studies [4, 6, 10], we found the risk
of contracting ESBL-PE to vary significantly between the
various parts of Africa. In addition, comparing our joint
data with two recent large reports [7, 11] providing sub-
region- and country-specific data enabled us to investigate
the current subregion- and country-specific knowledge
about ESBL-PE acquisition by travellers to Africa.
ESBL-PE colonization rates in northern Africa
Our pooled data showed the highest acquisition rates
(12/28; 42.9%) among visitors to Northern Africa, which
accords with the results from the study by Arcilla et al.
(42.0%) [11]; Ruppé et al. [7] did not report visitors to
this subregion. Similar (43–44%) rates have been reported
among Swedish travellers [3, 12]. Visitors to Egypt appear
to be at particularly high risk; 70.6% (12/17) of our sub-
jects, 80.0% (23/40) of those in a study by Arcilla et al.,
and 50% (19/38) of those in another by Tham et al. be-
came colonized [11, 14]. Moreover, all 12 travellers colo-
nized by ESBL-PE in Northern Africa had visited Egypt. It
is noteworthy that these proportions are as high as those
among travellers to India/South Asia in various investiga-
tions [4–8, 11]. Bassyouni et al. reported carriage rates as
low as 21% among healthcare workers in Egypt [17].
ESBL-PE colonization rates in middle Africa
To our knowledge, only one previous study has reported
ESBL-PE acquisition rates among visitors to Middle Africa;
Ruppé et al. [7] found 53.3% (24/45) of travellers to
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Table 1 Demographics and risk factors of ESBL-PE acquisition in pooled data on 396 travellers from Finland and the Netherlands
Univariate analysis Multivariable analysis
Characteristic total n (% of all) ESBL-PE(+) n (%) 95% CI (%)a P OR 95% CI P AOR 95% CI
Total 396 (100.0) 61 (15.4)
Gender
Male 159 (40.2) 24 (15.1) 10.1–21.2 1.0
Female 237 (59.8) 37 (15.6) 11.4–20.6 0.889 1.0 0.6–1.8
Ageb
Age, median, years 36 (IQR 27–53) 38.5 (IQR 25.5–55.5) 0.071 1.0 1.0–1-0 0.002 1.0 1.0–1.1
Study
Kantele et al. [6] 196 (49.5) 25 (12.8) 8.6–17.9 1.0 1.0
Paltansing et al. [4] 103 (26.0) 29 (28.2) 20.1–37.3 0.001 2.7 1.5–4.9 0.303 3.7 0.3–50.0
Reuland et al. [10] 97 (24.5) 7 (7.2) 3.2–13.5 0.158 0.5 0.2–1.3 0.962 1.1 0.1–25.1
Sampling method
Rectal swab 137 (34.6) 32 (23.4) 16.8–30.9 0.001 2.4 1.4–4.2 0.648 1.5 0.3–7.8
Stool sample 259 (65.4) 29 (11.2) 7.7–15.4 1.0
Year of travelb
(year of travel as a continuous variable) 0.909 1.0 0.8–1.2 0.609 0.8 0.3–2.1
2009 122 (30.8) 17 (13.9) 8.6–20.8
2010 74 (18.7) 8 (10.8) 5.1–19.2
2011 103 (26.0) 29 (28.2) 20.1–37.3
2012–2013 97 (24.5) 7 (7.2) 3.2–13.5
Destination subregion
Southern Africa 58 (14.6) 4 (6.9) 2.2–15.3 1.0 1.0
Northern Africa 28 (7.1) 12 (42.9) 25.8–61.2 < 0.001 10.1 2.9–35.8 0.001 12.4 3.1–57.3
Middle Africa 15 (3.8) 4 (26.7) 9.2–51.5 0.042 4.9 1.1–22.7 0.056 5.6 0.9–33.6
Eastern Africa 185 (46.7) 30 (16.2) 11.4–22.0 0.084 2.6 0.9–7.8 0.058 3.1 1.1–11.2
Western Africa 110 (27.8) 11 (10.0) 5.3–16.5 0.505 1.5 0.5–4.9 0.528 1.5 0.4–6.2
Antibiotics
no AB 352 (88.9) 44 (12.5) 9.3–16.2 1.0
AB 44 (11.1) 17 (38.6) 25.2–53.4 < 0.001 4.4 2.2–8.7
AB: beta-lactams
No 388 (98.0) 57 (14.7) 11.4–18.4 1.0 1.0
Yes 8 (2.0) 4 (50.0) 19.1–80.9 0.022 5.8 1.4–23.9 0.118 3.4 0.5–21.9
AB: fluoroquinolones
No 371 (93.7) 51 (13.7) 10.5–17.5 1.0 1.0
Yes 25 (6.3) 10 (40.0) 22–5-59.5 0.002 4.2 1.8–9.8 0.005 4.7 1.5–13.9
AB others (other than beta-lactams or FQ)/unknown
No 382 (96.5) 56 (14.7) 11.4–18.4 1.0 1.0
Yes 14 (3.5) 5 (35.7) 14.6–61.7 0.048 3.2 1.0–10.0 0.059 3.8 0.9–14.6
Doxycycline as antimalarial
No 362 (91.4) 56 (15.5) 12.0–19.4 1.0
Yes 34 (8.6) 5 (14.7) 5.5–29.0 0.906 0.9 0.4–2.5
Travellers’ diarrhoea (TD)
no TD 243 (61.4) 30 (12.3) 8.6–16.9 1.0
TD 153 (38.6) 31 (20.3) 14.4–27.1 0.034 1.8 1.0–3.1 0.033 2.1 1.1–4.1
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be colonized. In our pooled data, colonization rates in
Middle Africa ranked second (4/15; 26.7%) among the
subregions. In nonclinical samples obtained from local
populations, carriage rates as high as 59% have been
shown among healthy children in the Central African
Republic [18], and 44–57% among inpatient carers, hospital
workers and their household members in Cameroon [19].
ESBL-PE rates in eastern Africa
Colonization rates among travellers to Eastern Africa (30/
185; 16.2%) were lower than those reported by Arcilla et al.
(57/205; 27.8%) [11], Lubbert et al. (12/47; 25.5%) [8], and
Ruppé et al. (17/29; 56.8%,) [7]. Our moderate colonization
rates are supported by findings among local populations:
ESBL-PE carriage rates between 11.6 and 16.5% have
been reported for healthy community children in Tanzania,
[20, 21] and 5.3% for locals in Uganda, [22].
ESBL-PE colonization rates in western Africa
ESBL-PE acquisition rates in Western Africa appear moder-
ately low, but the results differ between studies: our pooled
data showed proportions (11/110; 10.0%) close to those
Table 1 Demographics and risk factors of ESBL-PE acquisition in pooled data on 396 travellers from Finland and the Netherlands
(Continued)
Univariate analysis Multivariable analysis
Characteristic total n (% of all) ESBL-PE(+) n (%) 95% CI (%)a P OR 95% CI P AOR 95% CI
Overnight hospitalisation abroad (information missing n = 1)
No 389 (98.5) 57 (14.7) 11.4–18.4 1.0
Yes 6 (1.5) 4 (66.7) 28.1–100 0.006 11.6 2.1–65.1 0.004 16.5 2.5–140.5
Duration of travel, (information missing n = 1)b
Median, days 19 (IQR 14–25) 18 (IQR 15–23) 0.828 1.0 1.0–1.0 0.276 1.0 1.0–1.0
a95% confidence intervals are profile likelihood confidence intervals for proportion of ESBL(+) with given risk factor
bstudied as a continuous variable in statistical analysis
Table 2 ESBL-PE colonization rates, occurrence of TD and antibiotic use in the pooled data on 396 travellers from Finland and the
Netherlands in relation to geographical subregion visited
All Northern Africa Middle Africa Eastern Africa Western Africa Southern Africa
n (%) n (%) n (%) n (%) n (%) n (%)
Kantele et al. (Finnish study) [6]
total no. of travellers to subregion (% of all) 196 3 (1.5) 4 (2.0) 86 (43.9) 78 (39.8) 25 (12.8)
ESBL-PE (+) 25 (12.8) 2 (66.7) 1 (25.0) 14 (16.3) 5 (6.4) 3 (12.0)
AB 34 (17.3) 1 (33.3) 1 (25.0) 13 (15.1) 15 (19.2) 4 (16.2)
TD 71 (36.2) 1 (33.3) 1 (25.0) 34 (39.5) 29 (37.2) 6 (24.0)
Paltansing et al. (Dutch study I) [4]
total no. of travellers to subregion (% of all) 103 13 (12.6) 7 (6.8) 54 (52.4) 12 (11.7) 17 (16.5)
ESBL-PE (+) 29 (28.2) 7 (53.8) 3 (42.9) 14 (25.9) 4 (33.3) 1 (5.9)
AB 8 (7.8) 2 (15.4) 1 (14.3) 3 (5.6) 2 (16.7) 0 (0.0)
TD 39 (37.9) 7 (53.8) 4 (57.1) 19 (35.2) 5 (41.7) 4 (23.5)
Reuland et al. (Dutch study II) [10]
total no. of travellers to subregion (% of all) 97 12 (12.4) 4 (4.1) 45 (46.4) 20 (20.6) 16 (16.5)
ESBL-PE (+) 7 (7.2) 3 (25.0) 0 (0.0) 2 (4.4) 2 (10.0) 0 (0.0)
AB 2 (2.1) 0 (0.0) 0 (0.0) 2(4.4) 1 (16.7) 0 (0.0)
TD 43 (44.3) 5 (41.7) 2 (50.0) 17 (37.8) 14 (70.0) 5 (31.3)
Combined total of the three studies
total no. of travellers to subregion (% of all) 396 28 (7.1) 15 (3.8) 185 (46.7) 110 (27.8) 58 (14.6)
ESBL-PE (+) 61 (15.4) 12 (42.9) 4 (26.7) 30 (16.2) 11 (10.0) 4 (6.9)
AB 45 (11.4) 3 (10.7) 2 (13.3) 18 (9.7) 18 (16.4) 4 (6.9)
TD 153 (38.6) 13 (46.4) 7 (46.7) 70 (37.8) 48 (43.6) 15 (25.9)
AB antibiotic use, TD travellers’ diarrhoea
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presented by Arcilla et al. (20/106; 18.9%) [11], while higher
rates have been found by Ruppé et al. (44/99; 44.4%) [7]
and Lubbert et al. (5/12; 38.5%) [8] among German
travellers to Western and Middle Africa. Moreover, in
the research by Frickmann et al., 27.1% (13/48) of European
military personnel with diarrhoea in Mali became colonized
by ESBL-PE [23]. As for local populations, colonization
rates of 22% have been reported for healthy volunteers in
Burkina Faso [24] and 33% for healthy community children
in Guinea-Bissau [25].
ESBL-PE colonization rates in southern Africa
Our low rates in Southern Africa (4/58; 6.8%) accord
with those found by Arcilla et al. (7/116; 6.0%) [11] and
Lubbert et al. (2/18; 11%) [8]. In our pooled data, the vast
majority had visited South Africa or Namibia. Consistent
with the low ESBL-PE acquisition rates, one study explor-
ing local populations in South Africa reported maternal
faecal carriage rates of 4.4% in South Africa [26].
Findings from multivariable analysis
Travellers’ diarrhoea
ESBL-PE acquisition rates among those who contracted
TD during travel (31/153; 20.3%) were higher than among
those without TD (30/243; 12.3%) (AOR 2.1; 95% CI 1.1–
4.1). This was expected, since TD was identified as a risk
factor in two of the three original studies [6, 10] and nu-
merous others [1, 3, 7, 8, 11, 12].
Antimicrobial medication
Forty-four (11.1%) travellers had taken antimicrobial
medications during travel. Of the Finns, 17.3% (34/
196) took antibiotics while this proportion was 5.0%
(10/200) among the Dutch. In multivariable analyses,
fluoroquinolone antibiotics were an independent risk
factor for ESBL-PE colonization (ESBL-PE(+) 40.0%;
AOR 4.7; 95% CI 1.5–13.9). Other antibiotic groups
did not reach statistical significance in the risk factor
analysis, yet the numbers of travellers using each individual
antibiotic type were small; eight had taken beta-lactams
(ESBL-PE(+) 50.0%; AOR 3.4, CI 0.5–21.9) and 14 other
antimicrobials (ESBL-PE(+) 35.7%; AOR 3.8 CI 0.9–14.6).
Ruppé et al. found beta-lactam usage to predispose to
colonization by ESBL-PE (20/25; 80%) [7].
Even though taken by 34 (8.6%) travellers as an anti-
malarial, doxycycline was not associated with increased
ESBL-PE rates (ESBL-PE(+) 5/34; 14.7%; AOR 0.9, 95% CI
0.4–2.5). This finding accords with other studies [7, 11].
However, these data do not allow conclusions on the
total impact of doxycycline on antimicrobial resistance,
Fig. 1 ESBL-PE acquisition rates in five African subregions; joint data on 396 travellers from Finland and the Netherlands. (Created with Mapchart.net)
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as these investigations only analysed the ESBL or CPE
feature of the Enterobacteriaceae; the potential to select
doxycycline-resistant strains in general or other types
of multidrug-resistant bacteria was not explored. Indeed,
we recently showed that fluoroquinolone intake predisposes
selectively to colonization by fluoroquinolone-resistant bac-
teria [27]. Thus, the effect of doxycycline on other bacteria
and travellers’ microbiota deserves further research.
Increasing age as risk factor
Increasing age proved an independent risk factor for
ESBL-PE colonization in Africa. Only two earlier reports
[3, 6] have described similar results, as opposed to several
others [7, 8, 11]. Moreover, in one study conducted among
returning travellers with diarrhoea, increasing age even
appeared protective [28]. The role of age remains unclear.
There may be other factors associated with increasing age,
such as co-medications/comorbidities or altered immune
response not covered in these studies that interfere with
the analyses in either direction. As the risk of bacteraemic
infections caused by resistant Enterobacteriaceae increases
with age [29], the risk factors in the older age groups
warrant further studies.
Overnight hospitalisation
In our joint data, overnight hospitalisation predisposed to
colonization with ESBL-PE. Although numerous retro-
spective studies have shown high colonization rates by
multiresistant bacteria among travellers hospitalized in
high-prevalence countries [30–32], to our knowledge, this
is the first study to actually show in a prospective setting
hospitalisation abroad as a risk factor for ESBL-PE acqui-
sition. In previous prospective traveller studies, overnight
hospitalisations has either not been analysed separately
from other health care contacts in the risk factor analyses
[7, 11] or the proportion of travellers requiring a stay in
hospital for treatment has been small or negligible (0–
0.5%) [3, 8]. In our data, six (1.5% of all subjects) needed
overnight hospitalisation.
Travel destination
In multivariable analysis, when compared to Southern
Africa, travel to Northern Africa was associated with higher
colonization rates. The rates presumably vary between sub-
regions and countries according to the background preva-
lence of the local populations [33]. They may also depend
on several other factors, such as local culture-related food
production and preparation habits and hygienic conditions
and, of course, whether the traveller contracts TD and takes
antibiotics (see above).
Other risk factors
Even though multiresistant Enterobacteriaceae have be-
come increasingly prevalent globally [33], colonization rates
were not found to increase during the study period (2009–
2013). Neither individual studies nor sampling techniques
were found statistically significant factors in the multivari-
able analysis. Travel duration was not seen to be associated
with increased risk in univariate or multivariable analysis.
This may be explained by a proportion of travellers becom-
ing colonized already on arrival and the carriage resolving
while abroad (Professor Kantele, unpublished observation).
Limitations of the study
As the data for the joint risk factor analysis were derived
from three separate studies, some data had been collected
Table 4 ESBL-PE colonization rates from the five studies [4, 6, 7, 10, 11] in relation to geographical subregion visited
All Northern Africa Middle Africa Eastern Africa Western Africa Southern Africa
Kantele et al. [6] (Finnish study) 2009–2010
ESBL-PE (+) among travellers n (% of all
visitors to subregion)
25/196 (12.8) 2/3 (66.7) 1/4 (25.0) 14/86 (16.3) 5/78 (6.4) 3/25 (12.0)
Paltansing et al. [4] (Dutch study I) 2011
ESBL-PE (+) among travellers n (% of all
visitors to subregion)
29/103 (28.2) 7/13 (53.8) 3/7 (42.9) 14/54 (25.9) 4/12 (33.3) 1/17 (5.9)
Reuland et al. [10] (Dutch study II) 2012–2013
ESBL-PE (+) among travellers n (% of all
visitors to subregion)
7/97 (7.2) 3/12 (25.0) 0/4 (0.0) 2/45 (4.4) 2/20 (10.0) 0/16 (0.0)
Ruppé et al. [7]2012–2013 (data on travellers visiting only one country)
ESBL-PE (+) among travellers n (% of all
visitors to subregion)
89/182 (48.9) N/A 24/45 (53.3) 21/37 (56.8) 44/99 (44.4) 0/1 (0)
Arcilla et al. [11]2012–2013
ESBL-PE (+) among travellers n (% of all
visitors to subregion)
118/508 (23.2) 34/81 (42.0) N/A 57/205 (27.8) 20/106 (18.9) 7/116 (6.0)
Combined total: ESBL-PE colonization rates 268/1086 (24.7) 46/109 (42.2) 28/60 (46.7) 108/427 (25.3) 75/315 (23.8) 11/175 (6.3)
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in differing formats rendering the results incomparable.
Moreover, although pooling served to increase the validity
and precision of study results, the data remained insuffi-
cient in some occasions for analysis in any great detail: In
Additional file 1: Table S1, we present the factors available
from two out of three studies [4, 6]: purpose of travel, diet
(omnivore or vegetarian), type of accommodation, use of
medications (antidiarrhoeals, proton-pump inhibitors,
and antiemetics) and contact with local health care (other
than hospitalisation). The five investigations appeared
heterogeneous in the forest plot analysis, however, in
the multivariable analysis of the pooled data, the inter-
action between subregions and studies was not found
statistically significant.
Information concerning mild gastrointestinal symptoms
in the ‘no TD’ group was only available for the Finnish vol-
unteers (48.8% of all ‘no TD’ cases). To pool the three
studies, we had to define TD as three or more stools per
24 h; milder diarrhoea cases were categorised as ‘no TD’,
although even mild TD also may predispose to ESBL-PE
acquisition.
Conclusions
ESBL-PE colonization rates in African subregions appear
moderate, with the exception of Northern Africa, espe-
cially Egypt. Also on this continent, however, TD and
antibiotic use increase the risk of individual travellers ac-
quiring ESBL-PE.
Additional file
Additional file 1: Table S1. Factors available in same format only from
the studies of Kantele et al. [6] and Paltansing et al. [4] and not included
in the pooled data of this report. (DOCX 16 kb)
Abbreviations
AB: Antibiotic; ESBL: Extended-spectrum beta-lactamase; ESBL-PE: Extended-
spectrum beta-lactamase-producing Enterobacteriaceae; TD: Travellers’ diarrhoea
Fig. 2 Forest plots of ESBL-PE acquisition rates from five studies in relation to geographical subregions. Excluded = no travellers to subregion in study
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